IIT-Roorkee researchers achieve breakthrough for treatment against systemic candidiasis infection

According to an estimate, systemic candidiasis accounts for 6.51 cases per 1,000 ICU admissions that is equivalent to 90,000 cases in India.

Published: 25th August 2020 08:14 PM  |   Last Updated: 25th August 2020 08:14 PM   |  A+A-

Dr. Soma Rohatgi with her Ph.D. scholar in IIT-R lab (Photo | EPS)

Express News Service

DEHRADUN: Researchers from IIT-Roorkee have demonstrated that vaccination using a fungal strain protein can protect against systemic candidiasis (C. tropicalis) infection in a mice model.

Systemic Candidiasis refers to a group of infections caused by drug-resistant fungal species. The study by Manisha Shukla and Soma Rohatgi, working at Molecular & Translational Immunology laboratory at the Department of Biotechnology, IIT Roorkee, has been published in the American Society for Microbiology journal ‘Infection and Immunity.’

"Due to a progressive shift towards non-albicans Candida species and the emergence of antifungal drug resistance, systemic candidiasis infections caused by Candidatropicalis species are a matter of concern, especially in tropical countries. As such, developing vaccines and alternative immunotherapies is of paramount importance” said professor Soma Rohatgi, chief author and assistant professor at IIT-Roorkee

According to lead author Manisha Shukla, “a subunit vaccine candidate can prove effective due to a variety of reasons”.

ALSO READ | IIT-Roorkee researchers develop sterilizing system for personal belongings

Systemic candidiasis refers to a spectrum of infections affecting blood, heart, eyes, brain, bones and many more. It is caused by yeast strains belonging to the Candida family.

Common symptoms of the disease include fever and chills that do not improve with antibiotics. Candidemia can also cause septic shock and therefore may be associated with symptoms such as low blood pressure, fast heart rate, and rapid breathing.

According to an estimate, it accounts for 6.51 cases per 1,000 ICU admissions that is equivalent to 90,000 cases in India.

The researchers have shown that Sap2-parapsilosis vaccination can improve mice survival during candidiasis by means of humoral and cellular immunity. The research also demonstrated that higher amounts of Sap2-specific antibodies are beneficial during systemic candidiasis. This research will pave the way for future studies in the development of anti-Candida vaccines.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

  • Shruti Chawla Dua

    Proud of you Roma...u have that passion we have seen in school days...very concentrated and focused towards your future..keep doing the good work...Also All the best ????
    1 year ago reply
flipboard facebook twitter whatsapp